Fixed|Duration Venetoclax plus Obinutuzumab New Standard of ...

Cost-effectiveness of a 12-month fixed-duration venetoclax ...

Active treatment costs for VenG and GClb were based on time on treatment in the CLL14 trial (12 cycles venetoclax or chlorambucil plus 6 cycles obinutuzumab; ...

Venetoclax plus bendamustine-rituximab or ... - Haematologica

Combination of the selective selective BCL-2 inhibitor venetoclax (Ven) with type II anti-CD20 antibody obinutuzumab (G; GA101) in a single-arm, ...

6-year results of CLL14: venetoclax-obinutuzumab for previously ...

Results demonstrated sustained efficacy and safety, establishing Ven-Obi as a preferred therapy option for CLL patients, including those with coexisting ...

Venetoclax-obinutuzumab is superior to chemoimmunotherapy in ...

... Bruton's tyrosine kinase (BTK) inhibitors and fixed duration venetoclax plus obinutuzumab have become standard treatment approaches, however ...

FLASCO / Treatment-Naïve CLL: Phase 3 Study of Sonrotoclax Plus ...

In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is ...

6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

One-year fixed-duration venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients with previously untreated chronic lymphocytic leukemia (CLL) ...

Effect of Fixed-Duration Venetoclax plus Obinutuzumab on ...

These patients were randomized 1:1 to receive either chlorambucil 0.5 mg/kg on day 1 and day 15 or 400-mg venetoclax (after 5-week ramp-up) for 12 cycles of ...

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Kirsten Fischer of the University of Cologne, Cologne, Germany, discusses data on a new fixed-duration targeted therapy with venetoclax plus ...

Insights into the MAJIC study: acalabrutinib + venetoclax ... - YouTube

... plus venetoclax versus venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL) ... GLOW trial: Is fixed duration ...

Chronic Lymphocytic Leukemia Clinical Trial - SurvivorNet

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Fixed-Duration Ibrutinib Plus Venetoclax Shows Continued Benefit ...

Long-term follow-up data from the CAPTIVATE study show continued progression-free survival benefit with fixed-duration ibrutinib plus ...

AstraZeneca's 9M and Q3 2024 results - Business Wire

Calquence fixed duration. Chronic lymphocytic leukaemia (AMPLIFY). Primary endpoint met. Fasenra. Eosinophilic chronic rhinosinusitis with nasal ...